CXCR3: Here to stay to enhance cancer immunotherapy?

EBioMedicine. 2019 Nov:49:11-12. doi: 10.1016/j.ebiom.2019.09.044. Epub 2019 Nov 2.

Authors

Meri Rogava¹, Benjamin Izar²

Affiliations

¹ Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, United States.
² Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, United States; Department of Medical Oncology and Center for Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States; Broad Institute of MIT and Harvard, Cambridge, MA, United States. Electronic address: bi2175@cumc.columbia.edu.

No abstract available

Publication types

Letter

MeSH terms

Biomarkers
Humans
Immunomodulation*
Immunotherapy
Neoplasms / immunology
Neoplasms / metabolism
Neoplasms / therapy
Receptors, CXCR3 / metabolism*
Treatment Outcome

Substances

Biomarkers
CXCR3 protein, human
Receptors, CXCR3

Grants and funding